The Israeli government’s stance on CBD has been nebulous at best. The compound was not specifically included in the country's medical cannabis regulations though CBD falls into this regulatory structure by default; as with all cannabinoids, CBD-only and CBD-dominant products can only legally be obtained by prescription from one's doctor at a pharmacy. While there is limited information on the availability of prescription Epidiolex for patients in Israel, it appears to be marketed and regulated in the same way as any pharmaceutical, rather than as a part of the medical cannabis market.
Efforts by Israel’s Ministry of Health to exclude CBD specifically from the country's Drugs Ordinance came very close to success before collapsing in December 2020, leading up to a change in government. It remains to be seen whether 2021 will usher in new attempts at legalizing or descheduling CBD, though the new administration is expected to be less warm to the idea. The lack of clarity around CBD reflects the country's historically confusing and contradictory regulatory approach, which was only reinforced with Israel’s decriminalization of cannabis, while import and export of non-medical hemp and CBD remain illegal.
Beginning April 2019, Israel decriminalized possession of the plant and allowed home grows of cannabis; while offenders will still face fines, they will not be arrested upon any of their first three offenses. Despite these changes, it does not appear likely that CBD sales outside the medical cannabis realm will be allowed in the near term.